Zhenyu Xu Sells 4,000 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Zhenyu Xu sold 4,000 shares of the stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $7.52, for a total transaction of $30,080.00. Following the sale, the insider directly owned 586,887 shares of the company’s stock, valued at $4,413,390.24. This represents a 0.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Zhenyu Xu also recently made the following trade(s):

• On Friday, August 7th, Zhenyu Xu sold 17,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.29, for a total transaction of $123,930.00.
• On Wednesday, August 5th, Zhenyu Xu sold 3,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.00, for a total transaction of $21,000.00.
• On Tuesday, August 4th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.92, for a total transaction of $69,200.00.
• On Monday, July 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total transaction of $22,800.00.
• On Monday, July 6th, Zhenyu Xu sold 7,393 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.17, for a total transaction of $38,221.81.

SOPHiA GENETICS Trading Down 1.6%

NASDAQ SOPH traded down $0.12 during mid-day trading on Friday, reaching $7.50. 193,279 shares of the stock were exchanged, compared to its average volume of 223,733. SOPHiA GENETICS SA has a one year low of $3.10 and a one year high of $7.88. The stock has a 50 day simple moving average of $5.84 and a 200-day simple moving average of $5.21. The stock has a market cap of $629.17 million, a P/E ratio of -6.52 and a beta of 0.96. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The firm had revenue of $23.31 million for the quarter, compared to the consensus estimate of $21.72 million. On average, analysts anticipate that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Perkins Capital Management Inc. purchased a new stake in shares of SOPHiA GENETICS during the 4th quarter worth approximately $49,000. Squarepoint Ops LLC purchased a new position in SOPHiA GENETICS in the third quarter valued at approximately $49,000. First Dallas Securities Inc. purchased a new position in SOPHiA GENETICS in the first quarter valued at approximately $50,000. Quadrature Capital Ltd bought a new position in SOPHiA GENETICS during the fourth quarter valued at $54,000. Finally, XTX Topco Ltd bought a new position in SOPHiA GENETICS during the fourth quarter valued at $55,000. 31.59% of the stock is owned by institutional investors.

Analysts Set New Price Targets

SOPH has been the subject of several recent analyst reports. Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. HC Wainwright lifted their target price on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Finally, BTIG Research boosted their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $10.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.